Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma (PRO-R-IPI)

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Status: Completed

Conditions: Diffuse Large B-cell Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01369784

PRO-R-IPI

Details and patient eligibility

About

The purpose of this study is to evaluate the prognostic value of clinical and biological factors in patients with refractory/relapsed Diffuse Large B-Cell Lymphoma.

Full description

The main aim of this study is to compare the prognostic value of R-IPI at diagnosis and relapse, relating it with the obtained response after second line

Enrollment: 158 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Age 18 > years old
• Patients with refractory/relapsed diffuse large B-cell lymphoma after first line treatment with rituximab, with or without transplantation. Patients must have finished a rescue treatment including rituximab
• Ability to understand and willingness to sign a written informed consent

Trial design

158 participants in 1 patient group

refractory/relapsed LDCBG

Description:

patients with refractory/relapsed diffuse large B-cell lymphoma